Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism

• Egile Nagusiak: Isabel Elías (Egilea), Itziar Oyagüez (Egilea), Luis Antonio Alvarez-Sala (Egilea), Fernando García-Bragadoa (Egilea), Andrés Navarro (Egilea), Paloma González (Egilea), Fernando de Andrés-Nogales (Egilea), Javier Soto (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2016-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: Cost-effectiveness analysis of a 6-month treatment of apixaban (10 mg/12h, first 7 days; 5 mg/12h afterwards) for the treatment of the first event of venous thromboembolism (VTE) and prevention of recurrences, versus low-molecular-weight heparins/vitamin K antagonists treatment (LMWH/VKA)...